---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077074"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T13:40:18.958049+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics completes $19M sale of manufacturing facilities to Cell Ready, exits manufacturing operations

## Summary
- Completed disposition of manufacturing facilities and equipment to Cell Ready for $19M on June 26, 2023.
- Transaction includes assignment of leases and sale of equipment; Cell Ready to offer employment to ~50 Marker employees.
- Pro forma results show net loss per share improvement: Q1 2023 by $0.01, FY2022 by $1.18, FY2021 by $2.11.
- Pro forma cash and cash equivalents increased to $25.2M from $6.4M as of March 31, 2023.
- John Wilson, Marker board member, is CEO and sole member of Cell Ready, creating a related-party transaction.

## SEC filing metadata
- accession: 0001104659-23-077074
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/0001104659-23-077074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/tm2319618d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077074
- JSON: https://secwatch.observer/filing/0001104659-23-077074.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077074.txt

## Key facts
- M&A Transactions
  Marker Therapeutics, Inc. completed a disposition involving Cell Ready, LLC for approximately $19.0 million (closed 2023-06-26).
  - Action: disposition
  - Counterparty: Cell Ready, LLC
  - Consideration: approximately $19.0 million
  - Closing: 2023-06-26
  source text: Company completed the disposition of the Purchased Assets to Cell Ready pursuant to the Transaction. The aggregate consideration paid for the Purchased Assets was approximately $19.0 million. In connection with the Transaction, Cell Ready plans to make offers of employment to approximately 50 of the Company's employees currently employed in its manufacturing,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465923077074/0001104659-23-077074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.